2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
77
Neoplasms
69
Prostatic Neoplasms
51
Colorectal Neoplasms
44
Lung Neoplasms
38
Carcinoma, Non-Small-Cell Lung
28
Hematologic Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
20
Head and Neck Neoplasms
19
Urinary Bladder Neoplasms
15
Ovarian Neoplasms
15
Multiple Myeloma
15
Stomach Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
11
Motor Activity
11
Leukemia, Myeloid, Acute
11
Glioblastoma
10
Uterine Cervical Neoplasms
9
Triple Negative Breast Neoplasms
9
Gastrointestinal Neoplasms
9
Colonic Neoplasms
9
Melanoma
8
Hematopoietic and Lymphatic System Neoplasm
8
Glioma
8
Esophageal Neoplasms
8
Carcinoma, Renal Cell
8
COVID-19
8
Anxiety Disorders
8
Anatomic Stage I Breast Cancer AJCC v8
8
Interventions
Temozolomide
11
Cyclophosphamide
11
Radiotherapy
7
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Cisplatin
6
Vincristine
5
Etoposide
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
sargramostim
3
Thiotepa
3
Melphalan
3
Carmustine
3
Automobiles
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
gallium Ga 68 dotatate
2
fludarabine
2
dactolisib
2
aldesleukin
2
Thalidomide
2
TH 302
2
Surveys and Questionnaires
2
Paclitaxel
2
Irinotecan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
Standard of Care
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled